$1.51
At close: Aug 26, 3:20 PM EDT
Comments
Loading...
Agile Therapeutics Inc COM PAR $0.0001 Analyst Ratings and Price Targets | OTC:AGRX | Benzinga
Agile Therapeutics Inc COM PAR $0.0001 Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Agile Therapeutics Inc COM PAR $0.0001 Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Agile Therapeutics Inc COM PAR $0.0001
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/18/2024 | Buy Now | — | Maxim Group | Naz Rahman27% | — | Downgrade | Buy → Hold | Get Alert |
| 09/22/2023 | Buy Now | — | Maxim Group | Naz Rahman27% | → $5 | Upgrade | Hold → Buy | Get Alert |
| 06/26/2023 | Buy Now | — | HC Wainwright & Co. | Oren Livnat62% | → $12 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2023 | Buy Now | — | HC Wainwright & Co. | Oren Livnat62% | → $12 | Reiterates | Buy → Buy | Get Alert |
| 12/30/2022 | Buy Now | — | HC Wainwright & Co. | Oren Livnat62% | $250 → $150 | Maintains | Buy | Get Alert |
| 07/26/2022 | Buy Now | — | Maxim Group | Naz Rahman27% | → $50 | Upgrade | Hold → Buy | Get Alert |
| 07/11/2022 | Buy Now | — | HC Wainwright & Co. | Oren Livnat62% | $125 → $250 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Agile Therapeutics Inc COM PAR $0.0001 (AGRX) stock?
The latest price target for Agile Therapeutics Inc COM PAR $0.0001 (OTC:AGRX) was reported by Maxim Group on March 18, 2024. The analyst firm set a price target for $0.00 expecting AGRX to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Agile Therapeutics Inc COM PAR $0.0001 (AGRX)?
The latest analyst rating for Agile Therapeutics Inc COM PAR $0.0001 (OTC:AGRX) was provided by Maxim Group, and Agile Therapeutics Inc COM PAR $0.0001 downgraded their hold rating.
When was the last upgrade for Agile Therapeutics Inc COM PAR $0.0001 (AGRX)?
The last upgrade for Agile Therapeutics Inc COM PAR $0.0001 happened on September 22, 2023 when Maxim Group raised their price target to $5. Maxim Group previously had a hold for Agile Therapeutics Inc COM PAR $0.0001.
When was the last downgrade for Agile Therapeutics Inc COM PAR $0.0001 (AGRX)?
The last downgrade for Agile Therapeutics Inc COM PAR $0.0001 happened on March 18, 2024 when Maxim Group changed their price target from N/A to N/A for Agile Therapeutics Inc COM PAR $0.0001.
When is the next analyst rating going to be posted or updated for Agile Therapeutics Inc COM PAR $0.0001 (AGRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Agile Therapeutics Inc COM PAR $0.0001, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Agile Therapeutics Inc COM PAR $0.0001 was filed on March 18, 2024 so you should expect the next rating to be made available sometime around March 18, 2025.
Is the Analyst Rating Agile Therapeutics Inc COM PAR $0.0001 (AGRX) correct?
While ratings are subjective and will change, the latest Agile Therapeutics Inc COM PAR $0.0001 (AGRX) rating was a downgraded with a price target of $0.00 to $0.00. The current price Agile Therapeutics Inc COM PAR $0.0001 (AGRX) is trading at is $1.51, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
